Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2021
Apr. 30, 2020
Apr. 30, 2021
Apr. 30, 2020
Income Statement [Abstract]        
Revenue $ 512,500
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 385,002
Research and development expenses (including non-cash share-based compensation expenses of $447,176, $458,132, $737,382 and $855,655, respectively) 1,022,176 1,228,790 1,849,827 2,719,378
General and administrative expenses (including non-cash share-based compensation expenses of $604,096, $651,954, $1,299,989 and $1,275,765, respectively) 1,415,106 1,441,347 2,948,084 2,580,628
Total operating costs and expenses 2,437,282 2,670,137 5,182,913 5,300,006
Loss from operations (2,437,282) (2,670,137) (4,670,413) (5,300,006)
Interest income 393 12,147 1,147 25,441
Net loss (2,436,889) (2,657,990) (4,669,266) (5,274,565)
Less: Net loss attributable to noncontrolling interest (38,038) (17,897) (62,124) (41,929)
Net loss attributable to common shareholders $ (2,398,851) $ (2,640,093) $ (4,607,142) $ (5,232,636)
Net loss per common share attributable to common shareholders: Basic and diluted $ (0.08) $ (0.12) $ (0.17) $ (0.25)
Weighted average common shares outstanding: Basic and diluted 28,669,475 21,155,505 26,887,974 20,927,212